Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Lancet Laboratories · Harvard University · +33 more institutions
Abstract
Abstract The SARS-CoV-2 epidemic in southern Africa has been characterized by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, while the second and third waves were driven by the Beta (B.1.351) and Delta (B.1.617.2) variants, respectively 1–3 . In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron, B.1.1.529) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for…
Citation impact
- FWCI
- 182.36
- Percentile
- 100%
- References
- 86
Authors
99- RVRaquel VianaCorresponding
Lancet Laboratories
- SMSikhulile Moyo
Harvard University, Botswana Open University, Botswana Harvard AIDS Institute Partnership
- DGDaniel G. Amoako
National Health Laboratory Service
- HTHouriiyah Tegally
University of KwaZulu-Natal
- CSCathrine Scheepers
National Health Laboratory Service, South African Medical Research Council, University of the Witwatersrand
Topics & keywords
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Transmission (telecommunications)
- Genome
- Virology
- Coronavirus disease 2019 (COVID-19)
- Population
- Neutralization
- Biology
- Good health and well-being
Funding
- BABill and Melinda Gates FoundationAwards: 203135, INV-018978
- RFRockefeller FoundationAwards: HTH 017, 2021 HTH 017 and 2020 HTH 062
- WTWellcome TrustAwards: 222754, 221003/Z/20/Z, Z/17/Z, 203135/Z/16/Z, 206298/Z/17/Z, 203135, 222574, 206298, 222574/Z/21/Z
- KIKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- DODepartment of Science and Innovation, South Africa
- DODepartment of Health and Social Care
- ECEuropean CommissionAwards: 725422, 203135, 101003688, COVID-19, 874850, 221003
- SASouth African Medical Research CouncilAwards: 203135, 203135/Z/16/Z, SHIPNCD 76756
- NHNational Health Laboratory ServiceAward: 221003/Z/20/Z
- FCForeign, Commonwealth and Development Office
- RKRobert Koch Institut
- NINational Institutes of HealthAwards: 203135, 5D43TW009610, COVID-19, 203135/Z/16/Z, U01 AI151698, AI151698
- CFCenters for Disease Control and PreventionAwards: 5U01IP001048, 5U01IP001048-05-00
- DFDirectorate for Biological Sciences
- MRMedical Research CouncilAwards: 203135, COVID-19
- BABiotechnology and Biological Sciences Research CouncilAwards: BB/M010996/1, M010996, M010996/1
- FIFogarty International CenterAward: 5D43TW009610
- EAEuropean and Developing Countries Clinical Trials Partnership